COMP <GO>
INGN vs ABBV // 10Y YIELD & FRED MACRO BETA
Inogen Inc (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: INGN 3
— ABBV 9
■ METRIC PARITY
LAST: $7.26 (+0.14%) • MKT CAP: $192.7M
macro-sensitivity
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INGN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INGN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 52.20% | 70.20% | -18.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.00% | 29.00% | -56.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.13% | 3.47% | -10.60 | ABBV | /fcf-yield <GO> |
| Operating Margin | -10.20% | 24.60% | -34.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 7.70% | 6.90% | +0.80 | INGN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.90% | 8.60% | -2.70 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.46 | 5.33 | -3.87 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.6 | 65.1 | +3.50 | INGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 7.9x | 113.1x | -105.20 | INGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $192.7M | $513.86B | -$513.67B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INGN REV | ABBV REV | INGN GROSS % | ABBV GROSS % | INGN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $295.3M | $61.16B | 52.2% | 70.2% | -$13.7M | $17.82B |
| FY 2024 | $278.8M | $56.33B | 55.5% | 70.0% | $2.6M | $17.83B |
| FY 2023 | $251.6M | $54.32B | — | — | -$3.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INGN // BETA —
ABBV // BETA 1.15